Journal of Human Reproductive Science
Home Ahead of Print Current Issue Archives
   Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size    Users online: 917


 
REVIEW ARTICLE Table of Contents   
Year : 2013  |  Volume : 6  |  Issue : 2  |  Page : 93-98
Current evidence supporting "letrozole" for ovulation induction


Department of Obstetrics and Gynecology, Kar Clinic and Hospital Pvt. Ltd, Bhubaneswar, Odisha, India

Correspondence Address:
Sujata Kar
Department of Obstetrics and Gynecology, Kar Clinic and Hospital Pvt. Ltd, Bhubaneswar, Odisha - 751 001
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-1208.117166

Rights and Permissions

Aromatase inhibitor "letrozole" was first introduced as a potential ovulation induction (OI) drug almost a decade back. Large number of studies has been published using letrozole for OI: In polycystic ovary syndrome (PCOS) women, clomiphene citrate (CC) resistant women, for intrauterine insemination and also in various protocols of mild stimulation for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI). Letrozole appears to be a good option, with its oral route of administration, cost, shorter half-life and negligible side effects. However, the verdict on efficacy and safety of letrozole is still uncertain. This review explores the current scientific data supporting letrozole for OI.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5055    
    Printed68    
    Emailed0    
    PDF Downloaded377    
    Comments [Add]    
    Cited by others 1    

Recommend this journal